MARAVIROC

SynDRA canonical compound SYN0009157 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	CCR5 \| CYP3A5
Mechanism of action	CC chemokine receptor antagonist
Indication	human immunodeficiency virus (HIV-1)
Disease area	infectious disease

All known targets

MD6P741W8A
UK-427857
maravirok
marawirok
celsentri
selzentry
Rel-maraviroc
Uk-427,857
Celsentri
Selzentry
UK 427857
UK-427,857
UNII-MD6P741W8A
CHEMBL256907
MVC
CHEMBL1201187
CHEBI:63608
4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide
Maraviroc [USAN]
Celsentri (TN)
Celsentri(TM)
PRO 140 & Maraviroc
Selzentry (TN)
Selzentry(TM)
UK-427,857 maraviroc (MVC)
Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide
PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide
4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide
[3H]maraviroc
SELZENTRY